| The metastatic infiltration at the metastasis/brain parenchyma-interface is very heterogeneous and has a significant impact on survival in a prospective study L Siam, A Bleckmann, HN Chaung, A Mohr, F Klemm, A Barrantes-Freer, ... Oncotarget 6 (30), 29254, 2015 | 96 | 2015 |
| Single-cell microRNA sequencing method comparison and application to cell lines and circulating lung tumor cells SM Hücker, T Fehlmann, C Werno, K Weidele, F Lüke, ... Nature communications 12 (1), 4316, 2021 | 56 | 2021 |
| Peroxisome proliferator-activated receptors (PPAR) γ agonists as master modulators of tumor tissue D Heudobler, M Rechenmacher, F Lüke, M Vogelhuber, T Pukrop, W Herr, ... International Journal of Molecular Sciences 19 (11), 3540, 2018 | 49 | 2018 |
| CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial A Mackensen, JBAG Haanen, C Koenecke, W Alsdorf, E Wagner-Drouet, ... Nature Medicine 29 (11), 2844-2853, 2023 | 39 | 2023 |
| Coronavirus disease 2019 induces multi‐lineage, morphologic changes in peripheral blood cells F Lüke, E Orsó, J Kirsten, H Poeck, M Grube, D Wolff, R Burkhardt, D Lunz, ... EJHaem 1 (1), 376-383, 2020 | 36 | 2020 |
| On the function of chitin synthase extracellular domains in biomineralization IM Weiss, F Lüke, N Eichner, C Guth, H Clausen-Schaumann Journal of Structural Biology 183 (2), 216-225, 2013 | 33 | 2013 |
| Metabolic imbalance of T cells in COVID-19 is hallmarked by basigin and mitigated by dexamethasone PJ Siska, SM Decking, N Babl, C Matos, C Bruss, K Singer, J Klitzke, ... The Journal of clinical investigation 131 (22), 2021 | 31 | 2021 |
| Clinical efficacy of a novel therapeutic principle, anakoinosis D Heudobler, M Rechenmacher, F Lüke, M Vogelhuber, S Klobuch, ... Frontiers in pharmacology 9, 1357, 2018 | 21 | 2018 |
| Abstract CT002: BNT211: a phase I trial to evaluate safety and efficacy of CLDN6 CAR-T cells and CARVac-mediated in vivo expansion in patients with CLDN6-positive advanced … JBAG Haanen, A Mackensen, C Koenecke, W Alsdorf, E Wagner-Drouet, ... Cancer Research 82 (12_Supplement), CT002-CT002, 2022 | 19 | 2022 |
| LBA38 BNT211-01: A phase I trial to evaluate safety and efficacy of CLDN6 CAR T cells and CLDN6-encoding mRNA vaccine-mediated in vivo expansion in patients with CLDN6-positive … A Mackensen, J Haanen, C Koenecke, W Alsdorf, E Wagner-Drouet, ... Annals of Oncology 33, S1404-S1405, 2022 | 18 | 2022 |
| Anakoinosis: correcting aberrant homeostasis of cancer tissue—going beyond apoptosis induction D Heudobler, F Lüke, M Vogelhuber, S Klobuch, T Pukrop, W Herr, ... Frontiers in Oncology 9, 1408, 2019 | 18 | 2019 |
| Secondary hemophagocytic lymphohistiocytosis and severe liver injury induced by hepatic SARS-CoV-2 infection unmasking Wilson’s disease: Balancing immunosuppression M Lubnow, B Schmidt, M Fleck, B Salzberger, T Müller, G Peschel, ... International Journal of Infectious Diseases 103, 624-627, 2021 | 13 | 2021 |
| Low-dose azacitidine, pioglitazone and all-trans retinoic acid versus standard-dose azacitidine in patients≥ 60 years with acute myeloid leukemia refractory to standard … D Heudobler, S Klobuch, F Lüke, J Hahn, M Grube, S Kremers, T Südhoff, ... Blood 134, 1382, 2019 | 11 | 2019 |
| Biomodulatory treatment regimen, MEPED, rescues relapsed and refractory classic Hodgkin’s disease F Lüke, DC Harrer, K Menhart, D Wolff, E Holler, D Hellwig, W Herr, ... Frontiers in Pharmacology 12, 599561, 2021 | 10 | 2021 |
| A randomized phase II trial comparing the efficacy and safety of pioglitazone, clarithromycin and metronomic low-dose chemotherapy with single-agent nivolumab therapy in … D Heudobler, C Schulz, JR Fischer, P Staib, T Wehler, T Südhoff, ... Frontiers in Pharmacology 12, 599598, 2021 | 10 | 2021 |
| Isolated metastasis of an EGFR-L858R-mutated NSCLC of the meninges: the potential impact of CXCL12/CXCR4 axis in EGFRmut NSCLC in diagnosis, follow-up and treatment F Lüke, R Blazquez, RF Yamaci, X Lu, B Pregler, S Hannus, K Menhart, ... Oncotarget 9 (27), 18844, 2018 | 10 | 2018 |
| Critical evaluation of molecular tumour board outcomes following 2 years of clinical practice in a Comprehensive Cancer Centre A Scheiter, F Hierl, F Lüke, F Keil, D Heudobler, S Einhell, M Klier-Richter, ... British Journal of Cancer 128 (6), 1134-1147, 2023 | 9 | 2023 |
| Identification of disparities in personalized cancer care—a joint approach of the German WERA consortium F Lüke, F Haller, K Utpatel, M Krebs, N Meidenbauer, A Scheiter, S Spoerl, ... Cancers 14 (20), 5040, 2022 | 8 | 2022 |
| Drug repurposing by tumor tissue editing F Lüke, DC Harrer, P Pantziarka, T Pukrop, L Ghibelli, C Gerner, ... Frontiers in Oncology 12, 900985, 2022 | 7 | 2022 |
| Continuous complete remission in two patients with acute lymphoblastic leukemia and severe fungal infection following short-term, dose-reduced chemotherapy F Lüke, DC Harrer, J Hahn, M Grube, T Pukrop, W Herr, A Reichle, ... Frontiers in Pharmacology 12, 599552, 2021 | 7 | 2021 |
